Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M275,690Revenue $M74,331Net Margin (%)21.6Z-Score5.1
Enterprise Value $M261,361EPS $5.7Operating Margin %28.1F-Score7
P/E(ttm))17.6Cash Flow Per Share $6.2Pre-tax Margin (%)28.2Higher ROA y-yY
Price/Book4.010-y EBITDA Growth Rate %4.3Quick Ratio2.0Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %3.5Current Ratio2.4Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %24.9ROA % (ttm)14.4Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)25.5Less Shares Outstanding y-yY
Payout Ratio %48.0Shares Outstanding M2,773ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJYacktman Focused Fund 2015-03-31 Reduce-0.11%$98.32 - $106.39
($101.69)
$ 100.28-1%Reduce -3.23%3,000,000
JNJDonald Yacktman 2015-03-31 Reduce-0.08%$98.32 - $106.39
($101.69)
$ 100.28-1%Reduce -2.08%8,432,672
JNJKen Fisher 2015-03-31 Add0.01%$98.32 - $106.39
($101.69)
$ 100.28-1%Add 0.31%10,456,816
JNJMario Gabelli 2015-03-31 Reduce$98.32 - $106.39
($101.69)
$ 100.28-1%Reduce -1.12%333,155
JNJJoel Greenblatt 2014-12-31 Add0.66%$96.78 - $109.07
($105.43)
$ 100.28-5%Add 5420.84%790,529
JNJRobert Olstein 2014-12-31 Reduce-0.17%$96.78 - $109.07
($105.37)
$ 100.28-5%Reduce -14.46%71,000
JNJJohn Rogers 2014-12-31 Add0.11%$96.78 - $109.07
($105.37)
$ 100.28-5%Add 17.80%632,132
JNJHOTCHKIS & WILEY 2014-12-31 Sold Out $96.78 - $109.07
($105.37)
$ 100.28-5%Sold Out0
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 100.28-3%Reduce -99.80%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 100.28-3%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 100.28-3%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 100.28-3%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 100.28-3%Reduce -3.70%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 100.28-3%Sold Out0
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 100.28-3%New holding14,319
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 100.28-3%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 100.28-1%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 100.28-1%Reduce -13.16%3,300,000
JNJRobert Olstein 2014-06-30 Reduce-0.31%$96.54 - $105.76
($101.02)
$ 100.28-1%Reduce -20.91%87,000
JNJDonald Yacktman 2014-06-30 Reduce-0.21%$96.54 - $105.76
($101.02)
$ 100.28-1%Reduce -5.50%9,045,902
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stoffels PaulusChief Scientific Officer 2015-04-28Sell187,250$100.73-0.6view
Fasolo PeterVP, Global Human Resources 2015-03-05Sell115,307$102.4-2.22view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-7.76view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-6.8view
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-3.83view
Caruso Dominic JVP, Finance; CFO 2014-08-21Sell30,000$104.3-4view
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.050.08view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.157.49view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.399.56view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.686.89view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
    North American Dividend Apr 26 2015 
    1002072 Apr 17 2015 
    What Were The Major Takeaways From Johnson & Johnson’s First Quarter Earnings? Apr 16 2015 
    5 Best U.S. Dividend Growth Stocks Apr 15 2015 
    Johnson & Johnson Beats Market Expectations Apr 15 2015 
    Johnson & Johnson: Currency Headwinds Impacts Q1 Results Apr 14 2015 
    Process Vs Outcome, Revisited Apr 07 2015 
    Johnson and Johnson: Well Positioned for Long-Term Growth Apr 06 2015 
    iRA Apr 06 2015 

    More From Other Websites
    Exclusive - Siemens healthcare unit probed by China regulator for bribery - sources May 02 2015
    Apple Inc. (AAPL), Pfizer Inc., and Wells Fargo & Co (WFC) Got A Vote of Confidence From Billionaire... May 02 2015
    Costco Accuses J&J Vision Care Unit of Price Fixing May 01 2015
    Anemic U.S. factory data points to moderate growth bounce May 01 2015
    JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report May 01 2015
    Don't Buy Growth Stocks - Weekend Wisdom May 01 2015
    Anemic U.S. factory data points to moderate growth bounce May 01 2015
    Geron Q1 Loss In Line with Estimates, Restructuring on Track - Analyst Blog May 01 2015
    FDA approves the Medicines Co's pain drug device Ionsys Apr 30 2015
    Apple Inc. (AAPL), Pfizer Inc. (PFE), Wells Fargo & Co (WFC): Billionaire Ken Fisher Bets on Tech,... Apr 30 2015
    Johnson & Johnson Just Gave New Parents Eight More Weeks of Paid Leave Apr 30 2015
    Cardinal Health Tops Q3 Earnings, Revenues; '15 View Stays - Analyst Blog Apr 30 2015
    Johnson & Johnson to Participate in the 2015 Deutsche Bank 40th Annual Health Care Conference Apr 30 2015
    Novartis’s Adjusted Earnings per Share Up 21.7% in 1Q15 Apr 30 2015
    Johnson & Johnson to Participate in the 2015 Deutsche Bank 40th Annual Health Care Conference Apr 30 2015
    Cardinal Health Profit Rises 16% Apr 30 2015
    Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE® Apr 29 2015
    Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE® Apr 29 2015
    Merck & Co. (MRK) Earnings Analysis: By the Numbers Apr 29 2015
    P&G’s $500M whack may hurt local marketing agencies Apr 29 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK